Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2012
- Total Asset Turnover since 2012
- Price to Book Value (P/BV) since 2012
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net earnings attributable to AbbVie Inc.1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2013 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of AbbVie Inc. Annual Report.
The price-to-earnings (P/E) ratio has exhibited considerable fluctuation over the observed period. Initially, the ratio increased from 11.51 in 2013 to a peak of 55.08 in 2015, before experiencing a substantial decline and subsequent volatility. More recently, the P/E ratio has shown a marked increase, reaching 94.06 in 2026.
- Initial Increase (2013-2015)
- From 2013 to 2015, the P/E ratio demonstrated a significant upward trend. This increase suggests that investors were willing to pay a progressively higher price for each dollar of earnings, potentially reflecting growing optimism regarding future profitability. The peak in 2015 represents the highest valuation observed throughout the period.
- Subsequent Volatility (2015-2018)
- Following the 2015 peak, the P/E ratio experienced a sharp decrease, falling to 17.01 in 2016. It then fluctuated, reaching 35.47 in 2018. This period indicates increased investor uncertainty or a correction in valuation after the earlier rapid increase. Earnings per share also contributed to this volatility, showing a decrease in 2014 and a low in 2015.
- Moderate Fluctuations (2019-2022)
- Between 2019 and 2022, the P/E ratio remained within a relatively constrained range, fluctuating between approximately 20 and 23. While some variation existed, it was considerably less pronounced than the earlier period. Earnings per share showed an increase in 2020 and a peak in 2022.
- Recent Increase (2023-2026)
- From 2023 onwards, the P/E ratio has risen substantially, increasing from 63.84 to 94.06. This recent surge suggests a renewed increase in investor confidence or a shift in market expectations regarding future earnings growth. However, it is notable that earnings per share decreased in 2023, 2024 and 2025, indicating the price increase is not directly correlated with earnings.
Overall, the P/E ratio demonstrates a pattern of significant swings, with periods of rapid increase followed by corrections and stabilization. The recent upward trend warrants further investigation to determine its sustainability and underlying drivers.
Comparison to Competitors
| AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | ||||||||||||
| Feb 14, 2025 | ||||||||||||
| Feb 20, 2024 | ||||||||||||
| Feb 17, 2023 | ||||||||||||
| Feb 18, 2022 | ||||||||||||
| Feb 19, 2021 | ||||||||||||
| Feb 21, 2020 | ||||||||||||
| Feb 27, 2019 | ||||||||||||
| Feb 16, 2018 | ||||||||||||
| Feb 17, 2017 | ||||||||||||
| Feb 19, 2016 | ||||||||||||
| Feb 20, 2015 | ||||||||||||
| Feb 21, 2014 | ||||||||||||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
AbbVie Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| AbbVie Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 20, 2026 | ||
| Feb 14, 2025 | ||
| Feb 20, 2024 | ||
| Feb 17, 2023 | ||
| Feb 18, 2022 | ||
| Feb 19, 2021 | ||
| Feb 21, 2020 | ||
| Feb 27, 2019 | ||
| Feb 16, 2018 | ||
| Feb 17, 2017 | ||
| Feb 19, 2016 | ||
| Feb 20, 2015 | ||
| Feb 21, 2014 | ||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
| AbbVie Inc. | Health Care | |
|---|---|---|
| Feb 20, 2026 | ||
| Feb 14, 2025 | ||
| Feb 20, 2024 | ||
| Feb 17, 2023 | ||
| Feb 18, 2022 | ||
| Feb 19, 2021 | ||
| Feb 21, 2020 | ||
| Feb 27, 2019 | ||
| Feb 16, 2018 | ||
| Feb 17, 2017 | ||
| Feb 19, 2016 | ||
| Feb 20, 2015 | ||
| Feb 21, 2014 | ||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).